351003-59-3

Usage

Chemical Properties

white to almost white powder

InChI:InChI=1/C6H5BrClNO2S/c7-4-1-2-6(5(8)3-4)12(9,10)11/h1-3H,(H2,9,10,11)

Upstream product

• 351003-52-6 4-bromo-2-chlorobenzene-1-sulfonyl chloride 
• 701-34-8 4-bromo-benzenesulfonic acid amide 

Downstream Products

• 896718-70-0 2-chloro-4-ethynyl-benzenesulphonamide 
• 1100767-90-5 4-acetyl-2-chloro-benzenesulfonamide 
• 1100767-89-2 N-[1-(4-acetylsulfamoyl-3-chloro-phenyl)-ethyl]-N'-(4-carbamimidoyl-phenyl)-malonamide trifluoroacetate 
• 1100767-91-6 4,N-diacetyl-2-chloro-benzenesulfonamide 
• 1100767-92-7 N-acetyl-4-(1-amino-ethyl)-2-chloro-benzenesulfonamide 

Relevant academic research and scientific papers

Regio- and chemoselective C-H chlorination/bromination of electron-deficient arenes by weak coordination and study of relative directing-group abilities

It's all relative: A practical and efficient PdII-catalyzed regio- and chemoselective chlorination/bromination has been developed for the facile synthesis of a broad range of aromatic chlorides. The reaction demonstrates excellent reactivity, good functional-group tolerance, and high yields. A preliminary study was conducted to evaluate relative directing-group abilities of various functionalities. Copyright

MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY

The present invention relates to compounds of the formula (I). The compounds of the formula (I) are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are inhibitors of the blood clotting enzymes, especially factor VIla and can in general be applied in conditions in which an undesired activity of factor VIla is present or for the cure or prevention of which an inhibition of factor VIla is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping

Virtual screening against a pCDK2/cyclin A crystal structure led to the identification of a potent and novel CDK2 inhibitor, which exhibited an unusual mode of interaction with the kinase binding motif. With the aid of X-ray crystallography and modelling,